InSite Vision Announces Positive Phase 1/2 Results for ISV-303 for the Reduction of Pain and Inflammation after Cataract Surgery - Drugs.com MedNews
Links shared publicly online about this topic.
- 421total visits
InSite Vision Announces Positive Phase 1/2 Results for ISV-303 for the Reduction of Pain and Inflammation after Cataract Surgery - Drugs.com MedNews
Once-Daily ISV-303 Demonstrates Statistical Significance over Vehicle and Numeric Superiority over Twice-Daily Xibrom InSite Vision s Late Stage Pipeline Now In
View full resource at drugs.com
Tags: Pain, Vision, Cataract, Drug, Surgery
Most Recently Shared on March 22, 2011 at 2:05 pm By:
InSite Vision Announces Positive Phase 1/2 Results for ISV-303 for the Reduction of Pain and Inflammation ... http://bit.ly/ihw5TV #drug
InSite Vision Announces Positive Phase 1/2 Results For ISV-303 For The Reduction Of Pain And Inflammation After Cataract Surgery
medicalnewstoday.com — “InSite Vision Incorporated (OTCBB:INSV) announced top-line results from its recently completed Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain” View full resource at medicalnewstoday.com
Most Recently Shared on March 23, 2011 at 4:05 pm By:
MNT Pain News Pain Management and Health News
InSite Vision Announces Positive Phase 1/2 Results For ISV-303 For The Reduction Of Pain And Inflammation After Catara... http://mnt.to/3SDr
Advertisement
